skip to Main Content

Setting a New Paradigm for Drug Toxicity


Introducing NEXEL’s History


Mar. ISO 9001 Certification
May. MOU with Biotoxtech for distribution of NEXEL’s cell products in Japan.
May. In-licensing of iPSC commercialization from Academia Japan (represents Kyoto University)
Jun. INNOBIZ Certification


Jan. Domestic Sales Launch
Apr. Exhibitor at BioKorea
May. Contract with BOYA medical for distribution of NEXEL’s products in China
May. Obtained 4 Government Research Grants (1.4 million dollars)
May. Ehxhibitor at International Korean Society for Biochemistry and Molecular Biology
Jun. Exhibitor at CPhI China
Aug. MOU with T&R Biofab for 3D Bio-Printing R&D using NEXEL’s Products
Sep. Research Grant Obtained for the Biotherapeutic Development (3 million $)


Feb. Certification of Venture Business (#20160101314)
Mar. Certification of Research Institute in NEXEL (#2016111120)
May. Sales contract for NEXEL’s products with IMPLAD in China
May. Selected as Best Value Company from Credit Guarantee Fund
Jun. MOU with Seoulin bio for domestic distribution of NEXEL’s products
Sep. MOU with Korea Institute of Toxicology (KIT) for drug screening using stem cells
Sep. Certification of excellent biotechnology from NICE (T6)
Nov. Licensed-in Cardiomyocyte Differentiation Patent from KIT
Dec. Patent Transfer from Korea Uni. (Registered: 2, Applications: 3, PCT: 1)


May. Company name changed to NEXEL, Co., Ltd.
Jul. Headquarters established within Korea University
Jul. MoU with Korea University for industry—academia partnership research


Sep. MOU with Institute of Medicinal Plant Development (IMPLAD) in China
Nov. Selection for family company in the institute of Animal Molecular biotechnology at Korea University


Mar. MOU with Anam Hospital at Korea University


Sep. NEXCELL Bio is Established

Back To Top